医药导报
醫藥導報
의약도보
HERALD OF MEDICINE
2014年
12期
1541-1544
,共4页
陈豫%褚倩%郭娟%黄玉%李文雯%田逸俊%夏曙%于世英
陳豫%褚倩%郭娟%黃玉%李文雯%田逸俊%夏曙%于世英
진예%저천%곽연%황옥%리문문%전일준%하서%우세영
依维莫司%癌,非小细胞肺%放射增敏%信号转导通路
依維莫司%癌,非小細胞肺%放射增敏%信號轉導通路
의유막사%암,비소세포폐%방사증민%신호전도통로
EVerolimus%Cancer,non_small cell lung%Radiosensitization%Signal transduction Pathway
目的:通过使用哺乳动物雷帕霉素靶蛋白mTOR抑制药依维莫司抑制A549细胞mTOR信号通路,研究依维莫司是否具有放射增敏作用。方法单纯放射治疗(放疗)或联合依维莫司作用于人非小细胞肺癌细胞系A549,采用噻唑蓝( MTT)法测定依维莫司对A549细胞抑制率并计算半数抑制浓度( IC50)。应用药物20%抑制浓度( IC20)作用24 h后X线2,4,6,8 Gy照射。计算细胞克隆存活分数及多靶单击模型拟合生存曲线,并计算平均致死剂量( D0)、准阈剂量(Dq)、照射剂量2 Gy下细胞存活分数(SF2)和放射增敏比(SER)。采用Western blot 方法检测γ_H2AX蛋白的表达,并分析相对灰度值。结果依维莫司联合放疗可明显提高A549细胞对射线的敏感性,依维莫司+照射组D0、Dq及SF2均明显低于单纯照射组,SER为1.36。依维莫司+照射组X线照射后24 h点γ_H2AX蛋白残余量明显高于单纯照射组。结论依维莫司抑制mTOR信号通路能够提高A549细胞的放射敏感性。
目的:通過使用哺乳動物雷帕黴素靶蛋白mTOR抑製藥依維莫司抑製A549細胞mTOR信號通路,研究依維莫司是否具有放射增敏作用。方法單純放射治療(放療)或聯閤依維莫司作用于人非小細胞肺癌細胞繫A549,採用噻唑藍( MTT)法測定依維莫司對A549細胞抑製率併計算半數抑製濃度( IC50)。應用藥物20%抑製濃度( IC20)作用24 h後X線2,4,6,8 Gy照射。計算細胞剋隆存活分數及多靶單擊模型擬閤生存麯線,併計算平均緻死劑量( D0)、準閾劑量(Dq)、照射劑量2 Gy下細胞存活分數(SF2)和放射增敏比(SER)。採用Western blot 方法檢測γ_H2AX蛋白的錶達,併分析相對灰度值。結果依維莫司聯閤放療可明顯提高A549細胞對射線的敏感性,依維莫司+照射組D0、Dq及SF2均明顯低于單純照射組,SER為1.36。依維莫司+照射組X線照射後24 h點γ_H2AX蛋白殘餘量明顯高于單純照射組。結論依維莫司抑製mTOR信號通路能夠提高A549細胞的放射敏感性。
목적:통과사용포유동물뢰파매소파단백mTOR억제약의유막사억제A549세포mTOR신호통로,연구의유막사시부구유방사증민작용。방법단순방사치료(방료)혹연합의유막사작용우인비소세포폐암세포계A549,채용새서람( MTT)법측정의유막사대A549세포억제솔병계산반수억제농도( IC50)。응용약물20%억제농도( IC20)작용24 h후X선2,4,6,8 Gy조사。계산세포극륭존활분수급다파단격모형의합생존곡선,병계산평균치사제량( D0)、준역제량(Dq)、조사제량2 Gy하세포존활분수(SF2)화방사증민비(SER)。채용Western blot 방법검측γ_H2AX단백적표체,병분석상대회도치。결과의유막사연합방료가명현제고A549세포대사선적민감성,의유막사+조사조D0、Dq급SF2균명현저우단순조사조,SER위1.36。의유막사+조사조X선조사후24 h점γ_H2AX단백잔여량명현고우단순조사조。결론의유막사억제mTOR신호통로능구제고A549세포적방사민감성。
Objective To exPlore the effect of mammalian target of raPamycin ( mTOR ) inhibitor eVerolimus on radiosensitiVity of human non_small cell lung cancer cell line in vitro by using eVerolimus to inhibit mTOR signaling Pathway of A549. Methods Human non_small cell lung cancer cell line A549 was subjected to radiation alone or in combination with eVerolimus treatment. The 50%inhibition concentration ( IC50 ) of eVerolimus in A549 cells was detected by methylthiazol tetrazolium ( MTT) assay in vitro. EVerolimus at the 20%inhibition concentration ( IC20 ) was used to Pretreat A549 cells for 24 h. Cells were then irradiated by X_ray with 2,4,6,8 Gy. The cell surViVal fraction was comPuted by clone formation. Cell surViVal curVe was fitted by multitarget one_hit model, and mean lethal dose ( D0 ), dose quasithreshold ( Dq ), surViVal fraction at 2 Gy ( SF2 ), and sensitization enhancement ratio (SER) were calculated. The exPression ofγ_H2AX was determined by Western blotting and then the relatiVe gray Values were analyzed. Results EVerolimus significantly imProVed the sensitiVity of A549 cells to radiation. The D0 , Dq and SF2 of eVerolimus+irradiation grouP were significantly lower than those of irradiation grouP. The SER was 1. 36. The residual amount of γ_H2AX Protein in the eVerolimus + irradiation grouP was significantly higher than that of the irradiation grouP. Conclusion EVerolimus inhibiting mTOR signaling Pathway can increase the radiosensitiVity of A549 cells.